Drug application
YEZTUGO (LENACAPAVIR SODIUM)
Drugs@FDA NDA 220018 · GILEAD SCIENCES INC
Key facts
| Drug name | YEZTUGO |
|---|---|
| Active ingredients | LENACAPAVIR SODIUM |
| Application type | NDA |
| Application number | 220018 |
| Company | GILEAD SCIENCES INC |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) |
| Marketing status | Prescription |
| Reference listed drug | Yes |
| Latest submission class | Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated |
| Latest submission status date | Jun 18, 2025 |
At a glance
- 1–9 Submissions
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: